nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2010 | Letter to the Editor

The diagnostic accuracy of ¹⁸F-FDG PET in cutaneous malignant melanoma

verfasst von: Bruno Krug, Anne-Sophie Pirson, Ralph Crott, Thierry Vander Borght

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Jiménez-Requena F, Delgado-Bolton RC, Fernández-Pérez C, Gambhir SS, Schwimmer J, Pérez-Vázquez JM, et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010;37:284–300. doi: 10.1007/s00259-009-1224-8.CrossRefPubMed

Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 2008;249:836–44. doi: 10.1148/radiol.2493080240.CrossRefPubMed

Bastiaannet E, Hoekstra OS, Oyen WJ, Jager PL, Wobbes T, Hoekstra HJ. Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases. Ann Surg Oncol 2006;13:919–26. doi:10.1245/ASO.2006.02.007.CrossRefPubMed

Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, et al. Utility of preoperative [(18)]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006;13:525–32. doi:10.1245/ASO.2006.02.008.CrossRefPubMed

Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006;141:284–8. doi:10.1001/archsurg.141.3.284.CrossRefPubMed

Horn J, Lock-Andersen J, Sjostrand H, Loft A. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2006;33:887–92. doi: 10.1007/s00259-006-0077-7.CrossRefPubMed

Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43:557–64. doi:10.1016/j.ejca.2006.11.014.CrossRefPubMed

Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24:1178–87. doi:10.1200/JCO.2005.03.5634.CrossRefPubMed

Romer W, Nomayr A, Greess H, Fiedler E, Platsch G, Schuler-Thurner B, et al. Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients. Nuklearmedizin 2006;45:88–95. doi: 10.1267/NUKL06020088.PubMed

10.

Iagaru A, Quon A, Johnson D, Gambhir SS, McDougall IR. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol 2007;9:50–7.CrossRefPubMed

11.

Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8:iii, 1–234.

12.

Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.CrossRefPubMed

13.

Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9.CrossRefPubMed

14.

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–48.PubMed

15.

Knottnerus JA, Muris JW. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol 2003;56:1118–28.CrossRefPubMed

16.

Smidt N, Rutjes AW, van der Windt DA, Ostelo RW, Reitsma JB, Bossuyt PM, et al. Quality of reporting of diagnostic accuracy studies. Radiology 2005;235:347–53.CrossRefPubMed

17.

Krug B, Crott R, Roch I, Lonneux M, Beguin C, Baurain JF, et al. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma. Acta Oncol 2010;49:192–200. doi:10.3109/02841860903440254.CrossRefPubMed

Titel: The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma
verfasst von: Bruno Krug
Anne-Sophie Pirson
Ralph Crott
Thierry Vander Borght
Publikationsdatum: 01.07.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1475-4

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2010

‘Running on empty’

Reply to: The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue

68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET

Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma

Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging